Merck & Co And Eisai Link Up For Combo Cancer Studies

Merck & Co and Eisai have signed a deal to assess various combinations of their immuno-oncology drugs in clinical trials. Merck's anti-PD-1 therapy, pembrolizumab (Keytruda) is to be tested in combination with Eisai's lenvatinib (Lenvima) and eribulin (Halaven) in multiple clinical studies.